
Julien Bezin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3625288/publications.pdf Version: 2024-02-01



IIIIIEN REZIN

#	Article	IF	CITATIONS
1	Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis. Cardiovascular Drugs and Therapy, 2023, 37, 271-276.	1.3	5
2	Chronic polypharmacy at all age: A populationâ€based drug utilization study. Fundamental and Clinical Pharmacology, 2022, 36, 405-413.	1.0	4
3	Antihypertensive and lipidâ€lowering drugs usage after primary stroke in a large representative sample of the French population. Fundamental and Clinical Pharmacology, 2022, 36, 742-749.	1.0	1
4	Antiherpetic drugs: a potential way to prevent Alzheimer's disease?. Alzheimer's Research and Therapy, 2022, 14, 3.	3.0	11
5	Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. European Journal of Cancer, 2022, 172, 85-95.	1.3	20
6	Antidopaminergic antiemetics and traumaâ€related hospitalization: A populationâ€based selfâ€controlled case series study. British Journal of Clinical Pharmacology, 2021, 87, 1303-1309.	1.1	1
7	Cost-effectiveness of screening of coronary artery disease in patients with type 2 DIABetes at a very high cardiovascular risk (SCADIAB study) rational and design. Cardiovascular Diabetology, 2021, 20, 63.	2.7	3
8	Evaluation of Covid-19 vaccines: Pharmacoepidemiological aspects. Therapie, 2021, 76, 305-309.	0.6	4
9	Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, , 1-10.	0.7	4
10	Risk of bradyarrhythmia related to ticagrelor: A systematic review and meta-analysis. Pharmacological Research, 2020, 160, 105089.	3.1	2
11	The Burden of Potentially Inappropriate Medications in Chronic Polypharmacy. Journal of Clinical Medicine, 2020, 9, 3728.	1.0	26
12	Polypharmacy: A general review of definitions, descriptions and determinants. Therapie, 2020, 75, 407-416.	0.6	38
13	DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus. Drug Safety, 2020, 43, 767-774.	1.4	4
14	Use of Lipid‣owering Drugs and the Risk of Cataract: A Populationâ€Based Nested Caseâ€Control Study. Clinical Pharmacology and Therapeutics, 2019, 105, 458-465.	2.3	10
15	The Reply. American Journal of Medicine, 2019, 132, e622.	0.6	0
16	Treatment Modalities and Survival in Older Adults with Metastatic Colorectal Cancer in Real Life. Journal of the American Geriatrics Society, 2019, 67, 913-919.	1.3	4
17	Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study. Frontiers in Pharmacology, 2019, 10, 265.	1.6	31
18	Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in France. Therapie, 2019, 74, 469-476.	0.6	6

Julien Bezin

#	Article	IF	CITATIONS
19	Pharmacoepidemiology of statins. Therapie, 2019, 74, 261-269.	0.6	5
20	Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort Study. American Journal of Medicine, 2019, 132, 740-748.e7.	0.6	34
21	Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Realâ€Life Setting. Clinical Pharmacology and Therapeutics, 2018, 103, 1038-1046.	2.3	6
22	An Automated System Combining Safety Signal Detection and Prioritization from Healthcare Databases: A Pilot Study. Drug Safety, 2018, 41, 377-387.	1.4	12
23	Risk of Serious Trauma with Glucoseâ€Lowering Drugs in Older Persons: A Nested Case–Control Study. Journal of the American Geriatrics Society, 2018, 66, 2086-2091.	1.3	2
24	Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome. Pharmacoepidemiology and Drug Safety, 2017, 26, 285-293.	0.9	18
25	Trends in the incidence of use of noninsulin glucoseâ€lowering drugs between 2006 and 2013 in France. Fundamental and Clinical Pharmacology, 2017, 31, 663-675.	1.0	8
26	The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2017, 26, 954-962.	0.9	382
27	Risk of discontinuation of antipsychotic longâ€acting injections vs. oral antipsychotics in realâ€life prescribing practice: a communityâ€based study. Acta Psychiatrica Scandinavica, 2017, 135, 429-438.	2.2	23
28	Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients. European Journal of Clinical Pharmacology, 2017, 73, 1655-1663.	0.8	4
29	False-positive results in pharmacoepidemiology and pharmacovigilance. Therapie, 2017, 72, 415-420.	0.6	21
30	National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1233-1241.	0.9	16
31	Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database. Drug Safety, 2017, 40, 1099-1107.	1.4	6
32	Impact of a public media event on the use of statins in the French population. Archives of Cardiovascular Diseases, 2017, 110, 91-98.	0.7	20
33	Pharmacological treatments of cardiovascular diseases: Evidence from real-life studies. Pharmacological Research, 2017, 118, 43-52.	3.1	15
34	Persistence to 5-year hormonal breast cancer therapy: a French national population-based study. British Journal of Cancer, 2016, 115, 912-919.	2.9	20
35	Antipsychotic long-acting injections: A community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation. Schizophrenia Research, 2016, 178, 58-63.	1.1	25
36	Choice of <scp>ICD</scp> â€10 codes for the identification of acute coronary syndrome in the French hospitalization database. Fundamental and Clinical Pharmacology, 2015, 29, 586-591.	1.0	50

Julien Bezin

#	Article	IF	CITATIONS
37	Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France. European Journal of Clinical Pharmacology, 2014, 70, 429-436.	0.8	36
38	Oral Morphine as an Alternative Substitution Treatment for Opioid Use Disorder, a Rare but Non-risk-free Use. Frontiers in Psychiatry, 0, 13, .	1.3	3
39	Potentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old. Pharmacoepidemiology and Drug Safety, 0, , .	0.9	2